Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.
Practice & Policy
Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.
Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.
Survival disparities for black patients with ovarian, colon, and breast cancer and childhood ALL suggest a need for efforts toward improved screening and treatment adherence in this population.
A recent analysis from the Breast Cancer Surveillance Consortium revealed that community oncology practices are neglecting to use MRI screening for at-risk women, and lower-risk women are being unnecessarily screened.
A new study has found that there are significant gaps in participation among people aged 75 and older in clinical trials of hematologic malignancies when considered against the incidence of these malignancies in this age group.
Patient access to NCI Cancer Centers is influenced by a complex mix of cancer center distribution and density, ethnicity, urbanicity, and travel time to care, according to a recently published statistical model.
Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.
The Commission on Future Research Priorities in the USA sets out 13 key priority areas to help focus the $2 billion of funding released to the NCI.
An increase in the number of approved cancer therapeutics has led to an associated increase in early-phase trials that have adopted a seamless approach.